EANS-News: SYGNIS Pharma AG SYGNIS further strengthens its patent position for
AX200 for the treatment of stroke
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Patents, Copyright & Trademarks
Heidelberg (euro adhoc) - SYGNIS further strengthens its patent position for
AX200 for the treatment of
stroke
Heidelberg, September 15, 2011 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard), a clinical stage biotech company researching and
developing innovative therapies for neurodegenerative diseases, today announced
that the European Patent Office has given two notices regarding their intention
to issue additional AX200-patents shortly. The respective patent applications
cover the use of AX200 for the acute and chronic stage of a stroke. These
additional patents will further strengthen SYGNIS´ patent portfolio of AX200
for the treatment of stroke which consists of six patent families.
The claims of the patent application for the treatment of acute stroke cover
the actual use and dosage of AX200 as applied in the current Phase II efficacy
study of AX200 (AXIS 2) and as intended to be used in clinical practice at a
later stage. With a scheduled expiry date of 2028, these claims complement the
key patent granted in Europe in 2006 and in the USA in 2009, covering the use
of AX200 for the treatment of stroke.
The claims of the second patent application cover the treatment of patients
with AX200 in the chronic stage of a stroke. They have a scheduled expiry date
of 2025 and complement SYGNIS´ IP-position in the early recovery phase
following a stroke.
Dr. Frank Rathgeb, CMO of SYGNIS commented: "The granting of these patents will
considerably strengthen the protection of our approaches for the treatment of
stroke with AX200 as well as the actual therapeutic regimen for the acute
treatment. Especially with regard to the top-line data of the AXIS 2-trial
which we expect to report towards the end of this calendar year, this improved
patent position will increase the overall value of the AX200 project and the
awareness amongst potential partners."
About AX200
AX200 is a biological molecule, developed by SYGNIS for the treatment of
neurodegenerative diseases. In the indication stroke it is the most advanced
drug candidate in SYGNIS´ product pipeline. AX200 is an endogenous protein. As
part of the body's own protective action the production of AX200 is boosted
after brain damage. If the molecule is given as a medication it increases the
existing endogenous response to the damage. SYGNIS pursues a multiple
neurotherapeutic approach in the development of AX200 for the treatment of
neurodegenerative diseases: AX200 stops neuronal cell death in the acute phase
of the disease while at the same time stimulating the regeneration of the
already damaged CNS through the stimulation of neurogenesis as well as
arteriogenesis and the reorganisation of neuronal networks.
About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical
company listed in the Prime Standard of the Frankfurt Stock Exchange. The
Company is focused on the research and development of innovative therapies for
the treatment of disorders of the Central Nervous System. SYGNIS´ core projects
are currently Acute Stroke for which SYGNIS´ lead clinical programme is AX200,
as well as the preclinical KIBRA-project for the treatment of different forms
of dementia. All these disorders are characterized by the fact that, as the
disease progresses, nerve cells are damaged and die. Although there is great
medical demand, there are currently no or only inadequate treatment options
available. Furthermore, a key element of the sustainable value creation of the
Company is the expansion of the product pipeline, which will be secured through
its own developments as well as in-licensing and acquisitions.
For further information please contact:
SYGNIS Pharma AG:
|Dr. Franz-Werner Haas |
|Senior Vice President Operations |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |
Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187
###
Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to
be total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG
may deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or
for any other reason.
###
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English